Patent Infringement Litigation in the U.S.

Patent infringement litigation in the United States is primarily governed by the Patent Act (35 U.S.C.), with enforcement handled through the federal courts, often involving complex questions of validity, scope, and damages. U.S. law distinguishes between direct infringement, contributory infringement, and inducement, and litigation often also involves claims of willful infringement to seek enhanced damages.

Case Law Analysis

1. eBay Inc. v. MercExchange, L.L.C., 2006 (Supreme Court)

Background

MercExchange held patents related to online auction technology. eBay used similar methods and MercExchange sued for patent infringement seeking an injunction.

Legal Issue

Whether permanent injunctions should automatically be granted in patent infringement cases.

Court Reasoning

Courts must apply the traditional four-factor test for injunctions:

Irreparable injury

Inadequate remedy at law

Balance of hardships

Public interest

Patent infringement does not automatically justify injunctions

Outcome

Supreme Court ruled no automatic injunction

Lower courts must evaluate case-by-case

Significance

Shifted the standard for injunctive relief in U.S. patent cases

Important for non-practicing entities (NPEs) or patent trolls

2. Apple Inc. v. Samsung Electronics Co., 2012

Background

Apple sued Samsung for smartphone design and utility patent infringement, including software features, touchscreen gestures, and icons.

Legal Issue

Scope of patent rights for design patents and utility patents

Calculation of damages for infringement

Court Reasoning

Both utility and design patents can justify damages

Willful infringement may justify enhanced damages up to 3×

Complex jury trials for calculating lost profits and royalties

Outcome

Initial damages of over $1 billion

Multiple appeals reduced damages and clarified design patent calculations

Significance

Landmark case clarifying design vs utility patents in tech

Illustrated complex multi-patent infringement litigation

Set precedent for enhanced damages and standard for willfulness

3. Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 1997 (Supreme Court)

Background

Hilton Davis sued Warner-Jenkinson for infringement under the doctrine of equivalents (DOE).

Legal Issue

Scope of doctrine of equivalents in determining infringement

Whether minor differences avoid literal infringement

Court Reasoning

Established that DOE allows finding infringement even if the accused product differs slightly from patent claims but performs substantially the same function

Must consider foreseeable equivalents and prosecution history estoppel

Outcome

Infringement found under DOE

Court clarified limits and application

Significance

Doctrine of equivalents crucial in chemical, pharmaceutical, and biotech patents

Prevents minor changes from circumventing patent protection

4. Medtronic, Inc. v. Mirowski Family Ventures, LLC, 2014 (Supreme Court)

Background

Dispute over medical device patents where Medtronic sought declaratory judgment of non-infringement while Mirowski claimed infringement.

Legal Issue

Burden of proof in patent infringement cases

Whether plaintiff or defendant must prove infringement

Court Reasoning

Accused infringer (Medtronic) bears burden to prove non-infringement

Patent holder always has initial presumption of validity

Outcome

Court clarified burden of proof lies with accused infringer

Non-infringement must be established by clear evidence

Significance

Fundamental rule in patent litigation strategy

Shapes settlement and trial approaches in infringement cases

5. i4i Limited Partnership v. Microsoft Corp., 2011 (Supreme Court)

Background

i4i sued Microsoft for infringing XML editing software patents. Microsoft argued the patent was invalid due to prior art.

Legal Issue

Standard for invalidating a patent in litigation

Whether clear and convincing evidence is required

Court Reasoning

Supreme Court ruled that a patent is presumed valid

Clear and convincing evidence required to invalidate a patent

Lower standard “preponderance of the evidence” insufficient

Outcome

Microsoft liable for infringement

$290 million damages awarded

Significance

Reinforced strong presumption of patent validity in litigation

Makes invalidity defenses harder for defendants

6. Amgen Inc. v. Sanofi, 2017

Background

Amgen alleged that Sanofi infringed its biologic patents related to cholesterol-lowering drugs (PCSK9 antibodies).

Legal Issue

Written description requirement

Whether Sanofi’s biologic falls within Amgen’s patent claims

Court Reasoning

Federal Circuit emphasized detailed disclosure in biotech patents

Patents must clearly describe claimed molecules or methods

Outcome

Partial infringement found

Clarified scope of written description and enablement in biologics

Significance

Critical for pharmaceutical and biotech patent litigation

Ensures clarity and prevents overly broad patent claims

7. KSR International Co. v. Teleflex Inc., 2007 (Supreme Court)

Background

KSR challenged Teleflex’s patent on adjustable pedals for cars, alleging obviousness.

Legal Issue

Standard for obviousness in patent validity

Court Reasoning

U.S. patent law requires non-obvious, inventive step

Supreme Court rejected rigid teaching-suggestion-motivation (TSM) test

Encouraged flexible, common-sense approach to obviousness

Outcome

Patent invalidated due to obviousness

Narrowed overly broad patent claims

Significance

Major impact on litigation involving obviousness challenges

Reduced risk of weak patents surviving litigation

Key Legal Principles in U.S. Patent Litigation

Summary

U.S. patent litigation is complex and multifaceted, balancing:

Strong patent protection to encourage innovation

Fair competition and limitations (injunctions, damages, obviousness, prior art)

Special rules for tech, pharma, and biotech patents

Key takeaways from cases:

eBay – Injunctions not automatic

Apple v. Samsung – Tech patents, enhanced damages

Warner-Jenkinson – Doctrine of equivalents

i4i v. Microsoft – Presumption of validity

Amgen v. Sanofi – Biotech disclosure standards

KSR v. Teleflex – Obviousness flexibility

Medtronic v. Mirowski – Burden of proof